granted EU Orphan Drug Designation for Rintatolimod
JUST GOT POSITIVE EU RECOMMENDATION
AIM (old 
HEB) granted EU Orphan Drug Designation for Rintatolimod for treatment of pancreatic cancer, Hemispherx Biopharma Europe.
Rintatolimod is Ampligen
This is going to trap shorts and when they PR this is going to explode!
ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2021_en.pdf
AIM (old HEB) granted EU Orphan Drug Designation for Rintatolimod for treatment of pancreatic cancer, Hemispherx Biopharma Europe. Rintatolimod is Ampligen
This is going to trap shorts and when they PR this is going to explode!
ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2021_en.pdf
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。